Corpus ID: 15632811

Vortioxetine (brintellix): a new serotonergic antidepressant.

@article{DAgostino2015VortioxetineA,
  title={Vortioxetine (brintellix): a new serotonergic antidepressant.},
  author={Andrew D'Agostino and Clayton D English and Jos{\'e} Antonio Ortiz Rey},
  journal={P \& T : a peer-reviewed journal for formulary management},
  year={2015},
  volume={40 1},
  pages={
          36-40
        }
}
Vortioxetine (Brintellix): a new serotonergic antidepressant. 
Vortioxetine exerts anti‐inflammatory and immunomodulatory effects on human monocytes/macrophages
TLDR
Whether vortioxetine, a multimodal anti‐depressive drug, was endowed with anti‐inflammatory and antioxidative activity, leading to immunomodulatory effects on human monocytes and macrophages is examined. Expand
Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
TLDR
In direct comparison to duloxetine, vortioxetine is found to have a smaller efficacy but had a lower risk of developing the common antidepressant-induced adverse effects. Expand
Randomized, double‐blind, placebo‐controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder
TLDR
This study evaluated the efficacy and safety of the multimodal antidepressant vortioxetine in Japanese patients with MDD and found it to be safe and effective. Expand
Is Vortioxetine an Advantageous Choice for Erectile Dysfunction? A Case Report
Commonly prescribed antidepressants are associated with sexual adverse effects predominantly reported as erectile dysfunction by men. The clinical dilemma of choosing the right antidepressant whileExpand
Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double‐blind, placebo‐controlled trial
TLDR
This study investigates the effects of vortioxetine vs placebo in enhancing the IBS patients' quality of life and concludes that the former is more beneficial than the latter. Expand
Vortioxetine-induced nausea and its treatment: a case report
TLDR
A case of nausea induced by vortioxetine along with its following treatment in a 32-year-old Italian patient with a diagnosis of bipolar disorder type 2, most recent depressive episode is described and the possible role of mirtazapine against antidepressant-induced nausea is suggested. Expand
Vortioxetine-Induced Hypomania: A Case Report.
TLDR
This case report is to present a patient who presented to psychiatry with depressive complaints for the first time, and a hypomanic shift that occurred two months after the start of vortioxetine with the diagnosis of major depressive disorder. Expand
Antistress and antidepressant properties of dapoxetine and vortioxetine.
TLDR
The obtained results confirm the antidepressant efficacy of used drugs upon both single and chronic administration and potential efficacy of these drugs administered in combination with stressed rats, and stress relieving properties of the study drugs are shown. Expand
Vortioxetine improved social and cognitive deficits in acute ketamine model of schizophrenia in rats
TLDR
Vortioxetine may have beneficial effects, especially on negative symptoms of schizophrenia, and it will be beneficial to confirm this study in different schizophrenia models of rodents and investigating the possible underlying mechanism. Expand
Vortioxetine versus other antidepressants in the treatment of Burning Mouth Syndrome: an open-label randomized trial.
TLDR
Vortioxetine was efficacious with a shorter latency of action and fewer AEs compared with other ADs, and was associated with a significant decrease in the VAS, T-PRI,HAM-A, HAM-D, CGI-I and CGI-E scores in the long-term. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
  • L. Citrome
  • Medicine
  • International journal of clinical practice
  • 2014
TLDR
The efficacy and safety of vortioxetine for the treatment of major depressive disorder (MDD) are described and the drug is described as safe and effective. Expand
Serotonergic drugs for depression and beyond.
TLDR
Various strategies that build upon SERT inhibition provide promise for novel therapeutic approaches to depression, including the possibility of targeting residual symptoms not well treated by Sert inhibition alone, and reducing side effects, such as sexual dysfunction. Expand
Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research
TLDR
In agreement with pharmacological studies, presynaptic and postsynaptic 5- HT1A-R activation appears necessary for anxiolytic and antidepressant effects, respectively, yet, neurodevelopmental roles for 5-HT 1A-Rs are also involved. Expand
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
TLDR
Vortioxetine demonstrated a favourable safety and tolerability profile and maintained effectiveness over 12 months of treatment, as with all open-label studies, the conclusions that can be drawn are limited by the lack of a placebo control. Expand
Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter.
TLDR
Findings support the hypothesis that alterations in 5-HT neurons play a role in the pathophysiology of depression. Expand
The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.
TLDR
Vortioxetine produced a markedly faster recovery of 5-HT neuronal firing than fluoxetine, at least partly due to 5- HT(3) receptor antagonism of vortioxettine in association with its reduced SERT occupancy. Expand
Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice.
TLDR
The obtained results indicate that blockade of 5-HT7 receptors may facilitate the anti-immobility effect of antidepressants in mice. Expand
Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
TLDR
Treatment with vortioxetine for 52 weeks was well tolerated, with no new safety signals identified, and change in the severity of depressive and anxiety symptoms was maintained throughout the study as reflected by a 24-item Hamilton Depression Scale total score of 8.2 at week 52. Expand
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
TLDR
In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment, indicating that 5m is a novel multimodal serotonergic compound, and5m is currently in clinical development for major depressive disorder. Expand
A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder
TLDR
It is shown that Lu AA21004 was effective in preventing relapse of MDD and was well tolerated as maintenance treatment. Expand
...
1
2
...